Ensysce Biosciences Inc (ENSC)
0.63
+0.02
(+2.92%)
USD |
NASDAQ |
May 16, 16:00
0.6387
+0.01
(+1.38%)
After-Hours: 20:00
Ensysce Biosciences Enterprise Value: 1.292M for May 16, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 16, 2024 | 1.292M |
| May 15, 2024 | 1.156M |
| May 14, 2024 | 0.7263M |
| May 13, 2024 | 0.9504M |
| May 10, 2024 | 0.4877M |
| May 09, 2024 | 0.6205M |
| May 08, 2024 | 0.7691M |
| May 07, 2024 | 0.8579M |
| May 06, 2024 | 0.8063M |
| May 03, 2024 | 0.7684M |
| May 02, 2024 | 0.8291M |
| May 01, 2024 | 1.125M |
| April 30, 2024 | 1.000M |
| April 29, 2024 | 1.011M |
| April 26, 2024 | 0.9444M |
| April 25, 2024 | 0.6599M |
| April 24, 2024 | 0.7502M |
| April 23, 2024 | 0.7479M |
| April 22, 2024 | 0.6167M |
| April 19, 2024 | 0.8442M |
| April 18, 2024 | 0.914M |
| April 17, 2024 | 1.129M |
| April 16, 2024 | 1.246M |
| April 15, 2024 | 1.493M |
| April 12, 2024 | 1.973M |
| Date | Value |
|---|---|
| April 11, 2024 | 2.038M |
| April 10, 2024 | 2.247M |
| April 09, 2024 | 2.230M |
| April 08, 2024 | 2.230M |
| April 05, 2024 | 2.413M |
| April 04, 2024 | 2.692M |
| April 03, 2024 | 2.396M |
| April 02, 2024 | 2.450M |
| April 01, 2024 | 2.230M |
| March 28, 2024 | 5.194M |
| March 27, 2024 | 5.266M |
| March 26, 2024 | 5.405M |
| March 25, 2024 | 5.255M |
| March 22, 2024 | 5.259M |
| March 21, 2024 | 5.127M |
| March 20, 2024 | 5.303M |
| March 19, 2024 | 5.487M |
| March 18, 2024 | 5.339M |
| March 15, 2024 | 5.219M |
| March 14, 2024 | 4.900M |
| March 13, 2024 | 4.900M |
| March 12, 2024 | 4.775M |
| March 11, 2024 | 5.025M |
| March 08, 2024 | 5.158M |
| March 07, 2024 | 1.876M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
0.1847M
Minimum
Sep 28 2023
344.04M
Maximum
Jul 02 2021
27.04M
Average
10.11M
Median
Enterprise Value Benchmarks
| NovaBay Pharmaceuticals Inc | 5.209M |
| Palatin Technologies Inc | 23.43M |
| iBio Inc | 16.17M |
| Theriva Biologics Inc | -8.844M |
| Oragenics Inc | 5.770M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.116M |
| Total Expenses (Quarterly) | 1.843M |
| EPS Diluted (Quarterly) | -0.55 |
| Earnings Yield | -598.4% |